PAREXEL and the Osaka International Cancer Institute form an alliance to advance clinical research in Japan

Madeira Public Health Service SESARAM EPERAM collaborates with the EU | mifuturonorcal

Alliance to drive greater efficiencies in oncology and hematology clinical trials

BOSTON and OSAKA, August 21, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global provider of biopharmaceutical services, and the Osaka International Cancer Institute announced today that they have formed an alliance to advance clinical development in Japan. The partnership will aim to drive greater efficiency in supporting patient recruitment for clinical trials in oncology and hematology, accelerating the development of innovative and effective new cancer treatments for patients.

« Oncology continues to be the largest therapeutic area in clinical trials today and is a priority for PAREXEL as we partner with customers to deliver new therapies to patients who need them, » said Shogo Nakamori, Corporate Vice President, Clinical Research Services, Asia Pacific, PAREXEL. “Osaka International Cancer Institute is a center of excellence for clinical trials in the Kansai region of Japan. Through this alliance, PAREXEL and the Osaka International Cancer Institute will work to drive greater efficiency for local and global biopharmaceutical companies, helping them accelerate the clinical development of innovative and effective new treatments in this challenging area of ​​the disease. »

« Progress in oncology clinical trials is critical in developing promising new therapies for patients in Japan and around the world, » said Dr. Nariaki Matsuura, president of the Osaka International Cancer Institute. “We are delighted to work with PAREXEL, an innovative partner with a broad presence in Japan and globally, with leading clinical and scientific expertise in oncology. Through this collaboration, the Osaka International Cancer Institute will have earlier access to new treatments, providing a wider range of potential treatment options for our patients and enabling us to make a strong contribution to the further advancement of cancer treatments. »

PAREXEL established operations in Japan in 1995 and has more than 1,300 employees based in Tokyo, Kobe and Osaka. PAREXEL is a leading biopharmaceutical services provider in the Asia-Pacific region, helping clients design drug development programs and conduct studies regionally and internationally. In the past five years alone, PAREXEL has led more than 2,300 oncology projects in more than 1.2 million patients at nearly 78,000 sites worldwide.

About Osaka International Cancer Institute
The Osaka International Cancer Institute was established in September 1959 as the Osaka Prefectural Center for Lifestyle-Related Diseases. In March 2017, it was renamed the Osaka International Cancer Institute and moved to its current location. The Center consists of the hospital division, the research division and the cancer control center. The hospital was the first public hospital in Japan to be certified as an advanced treatment hospital, and it retains that honor to this day. Among the best hospitals in the country, the Osaka International Cancer Institute offers various treatment options, including surgical, chemotherapy, radiation and immunotherapy treatments. The hospital has a high level of technical expertise and experience in cancer treatment, specializing in refractory cancers, such as pancreatic cancer. The research division has its own cancer cell processing/culturing method, CTOS/iCC, for the development of new cancer treatments, and the cancer control center serves as a cancer control public policy advisor for the Osaka Prefecture, leveraging data from the cancer registry. Together, the three divisions provide education and treatment for cancer patients.

About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of clinical research, consulting, medical communications, and expertise-based technology solutions and services to the global pharmaceutical, biotechnology, and medical device industries. Committed to providing solutions that accelerate time to market and peak market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trial management and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the integrated clinical development and regulatory information management process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 86 locations in 51 countries around the world and had approximately 19,370 employees in the third quarter. For more information about PAREXEL International visit

PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are property of their respective owners.

This release contains « forward-looking » statements regarding future results and events. To that end, all statements contained herein that are not statements of historical fact may be considered forward-looking statements. Without limiting the foregoing, the words « believes », « anticipates », « plans », « expects », « intends », « appears », « estimates », « plans », « will », « would », « may « should », « targets » and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. These factors and others are discussed in the section entitled « Risk Factors » of the The Company’s most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, a discussion of « Risk Factors » is incorporated by reference in this news release. expressly undertakes any obligation to update these forward-looking statements in the future.These forward-looking statements should not be relied upon as representing the Company’s estimates or opinions as of any date after the date of this press release.

# # #

PAREXEL Contacts:

Minors They are not
Phone: +81 3-5543-9500

Dan Robie
Phone: +1 781-434-4772

Ronald Aldridge
Phone: +1 781-434-4753

Osaka International Cancer Institute Contact:
Hiroshi Yamasaki, Public Relations
Phone: +81 6-6945-1181